直接抗病毒药物治疗后丙型肝炎合并或未合并HIV感染患者肠道菌群多样性与组成的改善
该研究纳入62例HCV单感染和24例HCV/HIV共感染接受elbasvir-grazoprevir治疗的患者,用16S rRNA测序分析治疗前和治疗后12周粪便标本。两组持续病毒学应答率相似(98.4% vs 95.8%)。治疗前患者肠道菌群多样性低于健康对照,获得持续病毒学应答者菌群失调改善,未应答者无改善。
要点
- DAAs治疗后获得持续病毒学应答者肠道菌群失调改善,未应答者无改善。
- 低纤维化程度应答者α多样性恢复至健康对照水平。
- 应答者中观察到有益菌增加和致病菌减少的相互变化。
核心结论
- 直接抗病毒药物在短期内可改善HCV感染患者的肠道菌群失调。
- 病毒清除后肠道菌群谱的有利变化可能有助于减少HCV相关并发症。
研究设计与样本
- 研究纳入62例HCV单感染和24例HCV/HIV共感染接受elbasvir-grazoprevir治疗的患者。
- 治疗前和治疗后12周粪便标本采用基于扩增子的16S核糖体RNA测序分析。
主要发现
- 单感染组和共感染组持续病毒学应答率相似(98.4% vs 95.8%)。
- 治疗前患者组细菌群落多样性低于健康对照且组成不同。
- HCV/HIV共感染者与HCV单感染者相比微生物α多样性相当但厚壁菌门-拟杆菌门比值降低。
- 获得持续病毒学应答者各纤维化阶段均观察到菌群失调改善,未应答者无改善。
- 低纤维化程度应答者α多样性恢复至健康对照水平,且有益菌增加、致病菌减少。
临床怎么用
- DAAs治疗获得持续病毒学应答可能伴随肠道菌群改善,尤其低纤维化程度患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The influence of direct-acting antivirals (DAAs) on the composition of gut microbiota in hepatitis C virus (HCV)-infected patients with or without human immunodeficiency virus (HIV) is unclear. METHODS: We enrolled 62 patients with HCV monoinfection and 24 patients with HCV/HIV coinfection receiving elbasvir-grazoprevir from a clinical trial. Fecal specimens collected before treatment and 12 weeks after treatment were analyzed using amplicon-based 16S ribosomal RNA sequencing. RESULTS: Sustained virological response rates in the monoinfection and coinfection groups were similar (98.4% vs 95.8%). Pretreatment bacterial communities in the patient groups were less diverse and distinct from those of healthy controls. Compared with HCV-monoinfected patients, HCV/HIV-coinfected individuals showed comparable microbial alpha diversity but decreased Firmicutes-Bacteroidetes ratios. The improvement of microbial dysbiosis was observed in responders achieving sustained virological response across fibrosis stages but was not found in nonresponders. Responders with a low degree of fibrosis exhibited a recovery in alpha diversity to levels comparable to those in healthy controls. Reciprocal alterations of increased beneficial bacteria and reduced pathogenic bacteria were also observed in responders. CONCLUSIONS: This study indicates a short-term effect of direct-acting antivirals in restoration of microbial dysbiosis. The favorable changes in gut microbiota profiles after viral eradication might contribute toward the reduction of HCV-related complications among infected individuals.
引用
- Chuaypen N, Jinato T, Avihingsanon A, et al. Improvement of Gut Diversity and Composition After Direct-Acting Antivirals in Hepatitis C Virus-Infected Patients With or Without Human Immunodeficiency Virus Coinfection. J Infect Dis. 2021. PMID: 33598686. doi:10.1093/infdis/jiab094
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。